TRIOAR is an antibody-based platform development company researching next-generation platform technology to improve existing antibody-based therapeutics. This platform technology maximizes the efficacy of antibody-based treatments by enhancing the therapeutic index. The company also provides novel treatment options for Antibody-Drug Conjugates (ADCs) through its proprietary core technology, improving drug delivery and reducing side effects.
Funding
Funding not disclosed
Founders
Product
Problem
Existing antibody-drug conjugates (ADCs) often suffer from suboptimal drug delivery to cancer cells and significant side effects due to off-target toxicity. This limits the efficacy and tolerability of targeted cancer therapies.
Solution
Trioar is developing a next-generation ADC platform designed to enhance the efficacy and safety of targeted cancer therapies. Their approach focuses on improving drug delivery specifically to cancer lesions while minimizing off-target effects. The platform incorporates novel tumor-targeting antibodies, optimized linkers, and potent toxins to induce rapid cancer cell death. By increasing drug absorption at the tumor site and reducing systemic exposure, Trioar aims to create ADCs with improved therapeutic index and patient outcomes.
Target Audience
Trioar's primary target audience includes pharmaceutical companies and research institutions focused on developing novel cancer therapeutics.
Features
- Tumor microenvironment (TME) targeting to increase drug delivery to the tumor site.
- Novel linker-toxin system for rapid induction of cancer cell death and improved drug stability.
- Antibody engineering to enhance tumor-targeting specificity.
- Payload optimization to maximize drug efficacy.